Hispolon, a phenolic pigment isolated from the mushroom species Phellinus linteus, has been investigated for anti-inflammatory,
antioxidant, and anticancer properties; however, low solubility and poor bioavailability have limited its potential clinical translation. In this study, the inclusion complex of
hispolon with Sulfobutylether-β-
cyclodextrin (SBEβCD) was characterized, and the
Hispolon-SBEβCD Complex (HSC) was included within the sterically stabilized
liposomes (SL) to further investigate its anticancer activity against
melanoma cell lines. The HSC-trapped-
Liposome (HSC-SL) formulation was investigated for its sustained drug delivery and enhanced cytotoxicity. The inclusion complex in the solid=state was confirmed by a Job’s plot analysis, molecular modeling, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR),
Proton nuclear magnetic resonance (NMR) spectroscopy, and scanning electron microscopy (SEM). The HSC-SL showed no appreciable deviation in size (<150 nm) and polydispersity index (<0.2) and improved drug encapsulation efficiency (>90%) as compared to control
hispolon liposomes. Individually incorporated
hispolon and SBEβCD in the
liposomes (H-CD-SL) was not significant in loading the drug in the
liposomes, compared to HSC-SL, as a substantial amount of free drug was separated during dialysis. The HSC-SL formulation showed a sustained release compared to
hispolon liposomes (H-SLs) and
Hispolon-SBEβCD
liposomes (H-CD-SLs). The anticancer activity on
melanoma cell lines (B16BL6) of HSC and HSC-SL was higher than in H-CD-SL and
hispolon solution. These findings suggest that HSC inclusion in the HSC-SL
liposomes stands out as a potential formulation approach for enhancing drug loading, encapsulation, and chemotherapeutic efficiency of
hispolon and similar water insoluble drug molecules.